Acute myeloid leukemia is a type of cancer that affects myeloid stem cells, which produce red blood cells, platelets and granulocytes, a type of white blood cell. Learn about the causes, symptoms and treatments of AML from MD Anderson, a top-ranked cancer center.

Acute myeloid leukemia (AML) treatment plans. Treatment for newly diagnosed AML patients typically focuses on chemotherapy. If intense rounds of chemotherapy are too difficult for the patient to undergo due to age or overall health, targeted therapy drugs may be given instead. Stem cell transplantation is also a treatment for AML.

2016年7月14日 · Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. “Acute” means that this leukemia can progress rapidly if not treated, and “myeloid” refers to the type of cell this leukemia starts from. While AML typically occurs in adults with median age of 67, MD Anderson does treat many adolescent and young adult AML patients.

Review and highlight treatment strategies based on the most current clinical practice guidelines, new approvals and approaches for patients with newly diagnosed acute myeloid leukemia (AML). Discuss strategies for implementing recent drug approvals and review evidence-based regimens for specific patients with relapsed or refractory AML ...

2022年1月20日 · We suggest defining patients with 10% to 30% blasts (AML/MDS) as eligible for both AML and MDS studies. This would permit empiric testing of the independent effect of blast percentage on outcome, allow patients access to more therapies, and potentially simplify the regulatory approval process.

2025年2月15日 · 国际共识分类（ICC）对骨髓增生异常综合征（MDS）和急性髓系白血病（AML）的分类，在以往分类的基础上进行了扩展，以完善两者的诊断标准，并识别特定的遗传学亚型。 对于 MDS，检测 SF3B1 基因突变（通常与环形铁粒幼细胞相关）的重要性以及 TP53 突变的不良预后现在已被纳入。 对于 AML，新增了遗传类别，并且通过识别具有 TP53 突变的 AML 以及与既往治疗或 MDS 相关基因突变的 AML，将分类扩展到包含更多具有临床意义的基因突变 …

FDA解除Magrolimab治疗MDS和AML的临床研究的限制. Magrolimab 是一种靶向 CD47 的研究性单克隆抗体，旨在干扰巨噬细胞上的 SIRPα 受体对 CD47 的识别，目的是阻断“不要吃我”信号被癌细胞用来避免被巨噬细胞摄取。

2024年12月13日 · 对于急性髓系白血病（AML），前50年的研究主要集中在阿糖胞苷联合蒽环类药物，并在策略方面取得了一定进展，包括异基因造血干细胞移植、大剂量阿糖胞苷、支持治疗措施和急性早幼粒细胞白血病患者的靶向治疗。 2017年是AML研究的转折点，此后已有12种不同机制的药物在美国获批治疗AML。 此外，口服decitabine-cedazuridine已获批作为骨髓增生异常综合征肠外去甲基化药物的生物等效替代药物，可用于AML治疗；Menin抑制剂、CD123抗体-药 …

Identify the prognostic factors in secondary acute myeloid leukemia (AML) that contribute to its heightened severity compared with patients diagnosed with de novo AML; Outline the criteria for diagnosing secondary AML.

2021年4月15日 · The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. After more than 40 years of slow progress in AML research, the US Food and Drug Administration has approved nine agents for different AML treatment indic …